Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
45% of adenocarcinoma tumors showed RASSF1A promoter methylation in comparison to 17% of squamous cell carcinomas and 22% of large cell carcinomas.
|
19926549 |
2009 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A promoter region CpG island methylation was detected in adenocarcinomas (55%), large cell carcinomas (25%), and squamous cell carcinomas (25%).
|
14511407 |
2004 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A methylation was more frequently observed in adenocarcinomas (28 of 72, 39%) than in squamous cell carcinomas (6 of 45, 13%, P = 0.0033).
|
15541815 |
2004 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A promoter methylation was associated with tumor grade (grade 3-4 vs 1-2: OR 2.31, 95% CI 1.12-4.77, P = 0.023), lymph node metastasis (yes vs no: OR 2.97, 95% CI 1.60-5.52, P = 0.001), tumor histology (squamous cell carcinoma vs adenocarcinoma: OR 0.49, 95% CI 0.22-1.08, P = 0.076), and HPV infection (positive vs negative: OR 0.45, 95% CI 0.28-0.73, P = 0.001).
|
29288321 |
2018 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A set of 4 genes, including CDH1 (E-cadherin), SFN (stratifin), RARB (retinoic acid receptor, beta) and RASSF1A (Ras association (RalGDS/AF-6) domain family 1), had their methylation patterns evaluated by MSP (Methylation-Specific Polymerase Chain Reaction) analysis in 49 fresh urinary bladder carcinoma tissues (including 14 cases paired with adjacent normal bladder epithelium, 3 squamous cell carcinomas and 2 adenocarcinomas) and 24 cell sediment samples from bladder washings of patients classified as cancer-free by cytological analysis (control group).
|
18702824 |
2008 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A significant association was found between TT genotype and methylation status of the RASSF1A gene in OSCC patients (p = 0.012).
|
20940365 |
2011 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
|
12839965 |
2003 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although in adenocarcinomas, methylation of RASSF1A and presence of human papillomavirus (HPV) type 16 or 18 sometimes coexisted, not a single case of HPV-16/18-positive squamous cell carcinomas had RASSF1A methylation.
|
12702579 |
2003 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Conversely, there was a trend toward a higher frequency of RASSF1A methylation in ADC than SCC.
|
21507233 |
2011 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Folate concentrations and methylation of LINE-1, RASSF1, and RUNX3 were significantly higher in adenocarcinoma compared to squamous cell carcinoma (SCC).
|
19764999 |
2009 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High down-regulation frequency was shown for RBSP3, ITGA9, VILL, APRG1/C3orf35 and RASSF1 (isoform A) genes (3p21.3 locus) in SCC.
|
23478628 |
2013 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
HPV infection does not correlate with RASSF1A methylation status in AC of the uterine cervix, but the absence of RASSF1A methylation in SCC of the uterine cervix coupled with the high incidence of HPV 16 infection in this subtype is in accord with previous reports.
|
12912945 |
2003 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of RASSF1A was detected in 30% of SCC, 12% of AC and in 1 of the 4 cancer cell lines but was absent in all normal cases.
|
12673680 |
2003 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the hypermethylation of RASSF1A or RUNX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC, particularly RASSF1A due to SCCs and RUNX3 due to ACs.
|
17606310 |
2007 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, inactivation of RASSF1A and p16 correlated well with an extended smoking habit (P=0.02), and exposure to asbestos (P=0.017) or squamous cell carcinoma (P=0.011), respectively.
|
15911247 |
2005 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LOH at 3p21.3-3p22.1 (where RASSF1A is located) was detected in only 12% of SCC and 0% of VC.
|
15689228 |
2005 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
|
19509163 |
2009 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
|
12082610 |
2002 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
|
19148529 |
2009 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The RASSF1A gene promoter was highly methylated in cancer tissues, and there were significant differences between normal esophagus tissues and esophageal squamous carcinoma (P < 0.05).
|
25886188 |
2015 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of all three TSGs were significantly different between NSCLC subtypes: RASSF1A and FUS1 expression levels were significantly lower in squamous cell carcinoma (SCC), and NPRL2/G21 in adenocarcinoma (AC).
|
26112163 |
2015 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of cancer-related gene methylation in SCCs was: CDH1 (95%), p16 (20%), p14 (15%), DAPK1 (15%), MGMT (15%), RB1 (5%), RASSF1 (5%), p15 (0%), PTEN (0%), PRDM2 (0%) and p53 (0%).
|
17034532 |
2006 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The frequency of KRAS mutation and RASSF1A methylation were significantly different between adenocarcinomas (P<0.001) and squamous cell carcinomas (P<0.001).
|
17360030 |
2007 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation frequency in normal, LSIL, HSIL, and SCC was significantly different (p<0.01) for eight genes (DAPK, HIC-1, HIN-1, MGMT, RAR-beta, RASSF1A, SHP-1, and Twist).
|
19836067 |
2010 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation of RASSF1A was inversely related to HPV infection in patients with HSIL/SCC (P=0.003).
|
17097722 |
2007 |